Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2024-06-14 EDT			5-day change	1st Jan Change
41.2 ^USD	-0.68%		-0.68%	-19.70%

06-14	Bristol Myers: FDA approval for treatment	CF
06-13	Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	MT

Neophore Limited announced that it has received funding from a group of investors

May 21, 2024

On May 22, 2024, Neophore Limited closed the transaction. The company amended the terms of the transaction and has received additional funds in its final tranche from new investor Bristol-Myers Squibb Company. The transaction was oversubscribed.

Latest news about Bristol-Myers Squibb Company

Bristol Myers: FDA approval for treatment	06-14	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	06-13	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	06-13	DJ
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	06-12	MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	06-12	MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	06-12	CI
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM	06-11
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	06-10	MT
Geron shares surge after U.S. FDA approves blood disorder drug	06-07	RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	06-05	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	06-05	CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	06-04	MT
Bristol Myers: positive results in liver cancer	06-04	CF
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial	06-04	CI
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company	06-03	CI
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	06-03	MT
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting	06-03	CI
Bristol Myers: presents advances in lung cancer	06-03	CF
Bristol Myers Squibb Presents Multiple New Analyses At 2024 Asco® Annual Meeting Highlighting Opdivo and Opdivo-Based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	06-03	CI
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	06-02	RE
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®?	06-01	CI
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	05-30	MT
Bristol Myers: FDA approval for Breyanzi	05-30	CF
US FDA allows use of Bristol's cell therapy for rare blood cancer	05-30	RE

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

11:30pm - European Hematology Association Meeting - Abstract No #S208

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.2 USD

Average target price

53.19 USD

Spread / Average Target

+29.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-19.70%	83.52B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals

Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Neophore Limited announced that it has received funding from a group of investors

EPS Revisions